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The aim of the present study is to address whether the molecular pathogenesis is identical among 
multiple basal cell carcinomas (BCCs) present in the same nevoid basal cell carcinoma syndrome 
(NBCCS) patient.  Patient 1 is a 61-year-old (yo) Japanese female whose clinical characteristics and 
ﬁndings of a genetic analysis of PTCH1 have been previously described.  Patient 2 is patient 1ʼs 64-yo 
sister who also suﬀered from NBCCS with a single base deletion at nucleotide 2613 in exon 16 
(c. 2613delC) in one PTCH1 allele.  Thirteen and 3 independent specimens of BCC were applied for a 
molecular analysis of loss of heterozygosity (LOH) in PTCH1 in patients 1 and 2,  respectively.  Of 
particular note is that all BCC specimens examined showed a loss of the wild-type allele of exon 16 in 
PTCH1,  thus indicating that LOH results in the biallelic disruption of PTCH1 in multiple BCCs that 
develop in an age- and location-independent manner in the same patient.  These results indicate that the 
germline single base deletion of PTCH1 (c. 2613 delC) is a ﬁrst hit and the LOH of the wild-type allele 
is a second hit,  implying that all 16 BCCs detected in these NBCCS sisters ﬁt the standard two-hit model.
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evoid basal cell carcinoma syndrome (NBCCS,  
also known as Gorlin syndrome,  OMIM 109400) 
is a rare autosomal dominant disorder characterized 
by a spectrum of developmental anomalies and a pre-
disposition toward the development of a variety of 
neoplasms,  including keratocystic odontogenic tumor 
(KCOT),  basal cell carcinoma (BCC),  ovarian ﬁbroma,  
desmoplastic medulloblastoma and meningioma [1].  
Congenital defects are associated with germline muta-
tions of the human homologue of the Drosophila seg-
ment polarity gene,  Patched 1 (PTCH1,  MIM 601309).  
The PTCH1 gene has been mapped to 9q22. 3 and 
consists of 23 exons spanning approximately 74kb 
encoding a 1447 amino acid transmembrane glycopro-
tein.  PTCH1 is a receptor for Hedgehog (HH),  and 
the HH signal is a key factor in embryonic develop-
ment and tumorigenesis.  Misregulation of signaling 
due to the inactivation of Sonic HH and PTCH1 has 
been implicated in the development of ciliopathy in 
patients with holoprosencephaly and NBCCS,  respec-
tively,  thus supporting the hypothesis that PTCH1 
acts as a tumor suppressor gene in this syndrome [2,  
3].
　 The inactivation of PTCH1 following the binding 
of Smoothened (SMO),  a seven-pass transmembrane 
homologue of G-protein-coupled receptors,  in turn 
activates a downstream signaling cascade involving 
GLI1,  GLI2,  GLI3 and SUFU to modulate the target 
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gene expression.  The constitutive activation of the HH 
pathway via mutations is a key molecular event in the 
development of neoplasms,  such as those involving the 
skin,  prostate and alimentary tract [3-5].
　 According to Knudsonʼs two-hit model of tumor 
suppressor genes [6],  the occurrence of 2 mutations 
in both alleles of the tumor suppressor gene or one 
mutation in one tumor suppressor gene allele accompa-
nied by the allelic loss of the remaining wild-type 
allele is required for neoplasm development.  Tumors 
in NBCCS patients are believed to develop according 
to the two-hit hypothesis [2,  7].  The ﬁrst ﬁt in 
NBCCS is a germline mutation in the PTCH1 gene,  
which is then followed by a second hit that involves a 
somatic inactivating mutation or deletion resulting in 
the constitutive activation of SHH signals.
　 Danaee et al.  found a high prevalence (60ｵ) of 
loss of heterozygosity (LOH) of the PTCH1 gene in 
patients with sporadic BCC [8].  However,  no study 
has documented how frequently the biallelic inactiva-
tion of PTCH1 occurs among multiple BCCs in the 
same NBCCS patient,  and nor has it been clearly 
demonstrated whether biallelic inactivation depends on 
the age of the patient or the location of the BCC.  We 
herein demonstrate that all BCCs examined in two 
NBCCS patients exhibited the biallelic loss of the 
PTCH1 gene and completely ﬁt the two-hit theory.
Patients and Methods
　 The previous clinical characteristics of patient 1 
have already been described [9].  Table 1 summarizes 
the recent clinical characteristics of patient 1 and the 
clinical features of patient 2.  Their father died because 
of skin cancer probably associated with NBCCS,  
whereas their mother has no history of skin cancer.  
Genomic DNA of basal cell carcinomas was extracted 
from formalin-ﬁxed,  paraﬃn-embedded tissues accord-
ing to phenol-chloroform extraction and ethanol pre-
cipitation methods and was used to detect LOH of the 
PTCH1 gene.  The peripheral blood mononuclear cells 
(PBMCs) were used as a DNA source for germline 
sequence analysis.  RT-PCR fragments ampliﬁed by a 
pair of primers,  PTCHex15 and PTCHex17 were 
cloned by pGEM-T easy vector systems according to 
the manufacturerʼs technical protocol (Promega,  
Madison,  WI,  USA) and sequenced by primer exten-
sion methods.  PBMCs were used as an RNA source.  
The primers used in the present study,  PTCHex15,  
PTCHex16,  PTCHex17,  rs10512248 and ivs19＋
1210 are described in Table 2.  Ampliﬁed DNA frag-
ments were recovered from a low melting temperature 
agarose gel (2ｵ) and subjected to a direct sequencing 
analysis using an automated DNA sequencing system 
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Table 1　 Clinical history of patients 1 and 2 with NBCCS
Patient 1 Patient 2
Age of onset of BCC 42-year-old (yo) 60 yo
Multiple BCC, excision More than 20 times 8 times
Location of BCC Head and face Head and face
Skull invasion of BCC 61 yo －
Dura invasion of BCC 61 yo －
Meningioma (meningothelial) 41 yo －
Epidermal cyst Excised twice NA
Calciﬁed falx cerebri ＋ NA
Palmar pits ＋ NA
Scoliosis ＋ NA
Hypertelorism ＋ NA
Rectal cancer (advanced) － 48 yo
Uterine leiomyoma － 48 yo
NBCCS,  nevoid basal cell carcinoma syndrome; BCC,  basal cell 
carcinoma; NA,  not available.
Table 2　 Primers used in the present study
Primer Sequences Product size (bp)
rs10512248F 5ʼ-AAGCCTGGAAAAGCTGATGGGTTG-3ʼ 143
rs10512248R 5ʼ-TCATTAGCAGACTTCTTACTTCAG-3ʼ
PTCHivs19F3-2 5ʼ-GCCAATAATATGGCAACAGTATTC-3ʼ 300
PTCHivs19R3 5ʼ-CTAGAGTTTAGAGACTGCAGTTAG-3ʼ
PTCHex16F2 5ʼ-AGGGTCCTTCTGGCTGCGAG-3ʼ 219
PTCHex16R2 5ʼ-TCAGTGCCCAGCAGCTGGAGTA-3ʼ
PTCHex15 5ʼ-ACCCGAATATCCAGCACTTAC-3ʼ 351
PTCHex17 5ʼ-TGCTGACCCAAGCCGTCAGG-3ʼ
ivs,  intervening sequence.
(Model 377,  Applied Biosystems,  Foster City,  CA,  
USA) [10].  Written informed consent for the gene 
analysis was obtained from both patients.  This study 
complied with the Declaration of Helsinki revised in 
2008 and was conducted according to the ethical 
guidelines presented annually by the Committee for 
Medical Experiment at Showa University.
Results
　 We screened age- and location-independent BCC 
specimens in patient 1 using direct sequencing of exon 
16 of the PTCH1 gene in order to analyze the heter-
ozygosity of c. 2613delC.  A representative case of 
BCC-9 is shown in Fig.  1.  The germline sequence 
shows c. 2613delC (Fig.  1A),  whereas no wild-type 
sequence is observed in BCC-9,  indicating LOH 
(Fig.  1B).  None of the 13 specimens examined in the 
present study exhibited any wild-type sequences.  Only 
the c. 2613delC mutation was identiﬁed,  implying that 
the PTCH1 gene was biallelically inactivated in all 
BCCs in patient 1.
　 Direct germline sequencing identiﬁed c. 2678G/A,  
resulting in p. 893R/H,  in patient 1 (Fig.  2A).  In 
order to examine whether c. 2678G/A is an SNP or a 
mutation,  we next analyzed the restriction fragment 
length polymorphism.  A restriction enzyme,  AccII,  cut 
CGCG but not the sequence,  CACG (c. 2678A).  
After we cut a fragment ampliﬁed with 2 primers,  
PTCH ex16F2 and PTCH ex16R2 (219bp),  using 
AccII,  a fragment of 171bp was obtained in the 
amplicon with c. 2678G,  although a 48-bp fragment 
was invisible,  while a 219-bp fragment remained in the 
amplicon with c. 2678A (Fig.  2C).  N2 in Fig.  2c 
indicates a healthy individual who shows the same 
restriction fragment length polymorphism as that in 
patient 1 (Fig.  2C).  Among 96 healthy chromosomes,  
2 were c. 2678A (data not shown),  thus indicating that 
c. 2678G/A is an SNP.  The germline sequence in 
patient 1 shows c. 2678G/A (Fig.  2A),  whereas only 
c. 2678G is observed in BCC-9 of patient 1 (Fig.  
2B).  Cloning of the RT-PCR fragment using the 
primer pair PTCHex15 and PTCHex17 followed by 
the sequenceing revealed that the wild type sequence 
of exon 16 was segregated with p. 893H/ c. 2678A 
(Fig.  3A),  and that p. 893R/c. 2678G was segregated 
with c. 2613delC (Fig.  3B),  thereby indicating that 
c. 2678A (p. 893H) was derived from the patientʼs 
mother.  These results indicate that the lost allele was 
the motherʼs wild type allele and that it retained a 
c. 2613delC-containing allele,  which causes a frame 
shift,  in BCC-9 of patient 1.  Other BCCs in patient 1 
showed the same results as those of BCC-9 (Table 3).
　 Exon 16 of the PTCH1 gene showed the same 
c. 2613delC in all three BCC specimens in patient 2 as 
that observed in patient 1 (Fig.  1).  We next searched 
for SNPs to determine the region of LOH in the 
PTCH1 gene,  and found two SNPs,  rs10512248 and 
ivs19＋1210,  in patient 2.  Although the germline 
sequence showed an SNP (Fig.  4A),  all three BCCs 
exhibited only T in the ivs19＋1210,  indicating the 
loss of the motherʼs wild type allele of the PTCH1 
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ATC  ATG   CCA  AAA  AT T   ACA  AGA
868 869 870 871 872 873 874 868 869 870 871 872 873 874
A B
Wild type    ATC   ATG   CCA  AAC  AAT   TAC  AAG
Mutation      ATC  ATG   CCA  AAA  AT T   ACA  AGA
Fig. 1　 A representative case of the biallelic disruption of the PTCH1  gene in BCC-9 in patient 1.  A,  Germline sequence of exon 16 of 
the PTCH1  gene.  The codon numbers are designated above the bars.  The arrow indicates the position of c.2613; B,  Sequence of exon 
16 of PTCH1  in BCC-9.  The arrow indicates the position of c.2613delC.
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B
Mutation (Father)
CCA AA AAT
870 c.2613delC
CGC 
p.893 R    exon 16 exon 17
A
Wild type (Mother)
CCA AAC AAT
870 871    872 
CAC 
p.893 H    
exon 16 exon 17
Fig. 3　 DNA sequencing of the RT-PCR fragment.  (A) TA cloning of the RT-PCR fragment following the DNA sequencing revealed that 
the wild type sequence in codon 871 is segregated with 893H,  whereas c.2613delC is associated with 893R (B).
895 894 893R/H 892 891 895 894 893R 892 891A B
C Pt1 N1 N2 N3 N4 N5 N6(bp) 
219-
171-
C/T C
Fig. 2　 LOH of PTCH1  in BCC-9 in patient 1.  A,  Germline sequence of exon 16 of the PTCH1  gene.  The codon numbers are desig-
nated above the bars.  The reverse complementary sequence is indicated.  The arrow indicates the position of c.2678G/A (p.893R/H); B,  
Sequence of exon 16 of PTCH1  in BCC-9. The arrow indicates the position of c.2678; C,  The agarose gel of exon 16 amplicons following 
digestion with AccII.  DNA extracted from peripheral blood mononuclear cells was used for the ampliﬁcation.  Band 219bp is the uncut 
amplicon; 171bp is the cut band.  Pt1 indicates patient 1,  and N indicates a healthy individual.
gene and thus LOH (Fig.  4B).  Such evidence,  in 
addition to c. 2613delC of the fatherʼs allele,  revealed 
the biallelic inactivation of the PTCH1 gene.  Despite 
of the SNP at 10512248 (Fig.  5A),  2 cases of BCC,  
BCC-2 (Fig.  5B) and BCC-3,  demonstrated reten-
tion of heterozygosity at rs10512248.  We next 
examined whether the histology of three BCCs,  
BCC-1,  BCC-2 and BCC-3 in patient 2 diﬀered and 
whether the histology of BCC diﬀered between 
patients 1 and 2.  Fig.  6 exhibits the BCC histologies 
of patients 1 and 2.  All BCCs (A-E) exhibit nests of 
basaloid cell proliferation with peripheral palisading.  
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Table 3　 Clinical characterictics and heterozygosity of PTCH1  gene in multiple basal cell carcinoma developed in NBCCS patients
Patients age/location rs10512248 c.2613delCexon 16
c.2678G/A
p.893R/H ivs19＋1210
Patient 1
　　BCC-1 45 (yo)/head LOH LOH
　　BCC-2 46/head LOH LOH
　　BCC-3 49/head LOH LOH
　　BCC-4 49/face LOH LOH
　　BCC-5 50/face LOH LOH
　　BCC-6 51/face LOH LOH
　　BCC-7 52/head LOH LOH
　　BCC-8 52/head LOH LOH
　　BCC-9 55/head LOH LOH
　　BCC-10 55/face LOH LOH
　　BCC-11 57/head LOH LOH
　　BCC-12 61/head LOH LOH
　　BCC-13 61/head LOH LOH
Patient 2
　　BCC-1 61/head (L) LOH LOH NA LOH
　　BCC-2 61/head (R) ROH LOH NA LOH
　　BCC-3 61/head (L) ROH LOH NA LOH
BCC,  basal cell carcinoma; LOH,  loss of heterozygosity; ROH,  retention of heterozygosity; NBCCS,  nevoid basal cell carcinoma 
syndrome; ivs,  intervening sequence; yo,  year-old; NA,  not available.
A B
ivs19＋1210
ivs19＋1210
C/T
T
Fig. 4　 Allelic loss of ivs19＋1210 in PTCH1  in BCC-1 in patient 2.  (A) Germline sequence of ivs19＋1210 of the PTCH1  gene.  The 
arrow indicates the position of ivs19＋1210.  (B) Sequence of BCC-1.
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A B
D E
C
Fig. 6　 Histopathology of BCC in patient 2 (A-C) and patient 1 (D,  E).  (A-C) Histology of BCC-1,  -2 and -3 in patient 2 is shown in 
A,  B and C,  respectively.  Dural invasion of BCC and skull invasion of BCC in patient 1 are shown in D and E,  respectively.  An asterisk 
indicates dura (D) and central necrosis (E) of BCC.
A B
rs10512248 rs10512248
C/A C/A
Fig. 5　 The retention of heterozygosity of rs10512248 in PTCH1  in BCC-2 in patient 2; A,  Germline sequence of rs10512248 in the 
PTCH1  gene.  The arrow indicates the position of rs10512248; B,  Sequence of BCC-2.
In patient 2,  all BCCs are small,  measuring approxi-
mately 2mm in diameter,  and they show no histologi-
cal diﬀerences among them (Fig.  6A-C).  The histol-
ogy of BCCs in these patients was indistinguishable 
from that of nonsyndromic BCCs.  However,  central 
necrosis was observed in the nest of BCCs that 
invaded the skull in patient 1 (E).
　 No SNPs for the PTCH1 gene,  rs2297697,  
rs10988802,  rs357564,  rs10512248 or ivs19＋1210 
were observed (rs10512248 was A and ivs19＋1210 
was T).  These markers could not be used to identify 
the lost allele of PTCH1.  Hence,  the region of allelic 
loss of PTCH1 was not available in patient 1.  
Rs10512248 was only A and ivs19＋1210 was only T 
in patient 1,  implying that the mutation allele derived 
from her father is A and T,  respectively.  The muta-
tion allele in patient 2 is the same as that in patient 1,  
suggesting that rs10512248 is C and ivs19＋1210 is C 
in the wild-type allele derived from her mother in 
patient 2.  These results are summarized in Fig.  7 and 
Table 3.  Patients 1 and 2 each inherited a diﬀerent 
PTCH1 allele from their mother (Fig.  7).
Discussion
　 Keratocystic odontogenic tumors (KCOTs) are 
aggressive jaw neoplasms that occur sporadically or in 
association with NBCCs.  Levanat et al.  originally 
reported that the tumorigenesis of KCOT ﬁts a two-
hit model in patients with Gorlin syndrome [7].  
Recently,  Pan et al.  examined the LOH in 44 patients 
with KCOT (15 NBCCS-related cases and 29 spo-
radic cases).  Among these,  13 were identiﬁed to ﬁt 
the two-hit model,  14 conformed to the one-hit model 
and the remaining 17 showed no alterations in PTCH1.  
Of particular note is that the distributions of the two-
hit,  one-hit and non-hit cases diﬀered signiﬁcantly 
between the NBCCS and nonsyndromic patients.  The 
incidences for two-hit,  one-hit and non-hit inactivation 
of PTCH1 were 53.3ｵ,  33.3ｵ and 13.3ｵ of the 
NBCCS-associated KCOT patients,  respectively.  In 
contrast,  these mechanisms were observed in 17.2ｵ,  
31ｵ and 51.7ｵ of the sporadic KCOT patients,  
respectively.  The two-hit inactivation of PTCH1 is 
highly prevalent in patients with NBCCS-associated 
KCOT,  although cases of KCOT that lack any PTCH1 
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ivs19+1210rs10512248
p.893R/H. c.2678G/A
Fa
Mo
c.2613delC (exon 16)
Fa
Mo
R
H
R
R
＊
＊
＊
T
T
10 Kb
A
A
PTCH1 NM_001083603.1
Patient 1
Patient 2
T
C
A
C
Loss in
BCC 
Loss in
BCC 
Fig. 7　 An integrated germline map of the PTCH1  gene in patients 1 and 2.  Fa and Mo indicate haplotypes derived from the father and 
mother,  respectively.  The asterisk denotes the c.2613delC mutation in exon 16 (shown in blue),  and the box designated as a loss in BCC 
is a deleted haplotype in BCC.
hits do exist [11].  The standard two-hit hypothesis 
has been demonstrated not only in patients with KCOT 
but also in those with NBCCS-associated meningioma.  
Kijima et al.  reported biallelic mutations,  c. 290dupA 
(germline) and c. 307delG (somatic),  in meningioma 
that developed in an NBCCS patient [12].  Koch et al.  
reported that the Gorlin syndrome-associated hepatic 
mesenchymal tumor ﬁts the two-hit model [13].  
However,  many types of tumors develop in patients 
with NBCCS.  Therefore,  it remains to be addressed 
whether the biallelic inactivation of PTCH1 is involved 
in the molecular pathogenesis of all NBCCS-associated 
tumors.  The NBCCS patients evaluated in the pres-
ent study exhibited not only multiple BCCs but also 
meningioma in patient 1 and rectal cancer and uterine 
leiomyoma in patient 2.  Molecular analyses for 
heterozygosity of the PTCH1 gene in these tumors 
might provide important evidence for molecular 
tumorigenesis; however,  the results were inadequate 
due to the low quality of DNA in these tumors.
　 In conclusion,  the current study showed the bial-
lelic disruption of the PTCH1 gene in all 16 BCCs 
examined in two NBCCS patients.  Our results pro-
vide interesting results indicating that the molecular 
pathogenesis of BCC completely ﬁts the two-hit the-
ory.  The ﬁrst hit is a germline mutation of c. 2613delC 
and the second hit is a somatic loss of wild-type allele 
in PTCH1,  resulting in the lack of expression of nor-
mal PTCH1 protein,  then leading to the activation of 
the HH pathway and ﬁnally the formation of BCC.  In 
the present study,  immunohistochemical analysis of 
PTCH1 in BCC could not be conducted because no 
adequate antibodies were available.  Thus it remains 
to be addressed whether PTCH1 is actually synthe-
sized and expressed on the cell surface.
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